Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

13 Jul 2022

Abstract excerpt

High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has a low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed identification of drivers for neuroblastoma development. Using this approach, combined with gene dosage impact on expression and survival, we identified ribonucleotide reductase subunit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35857500
DOI: 10.1126/sciadv.abn1382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionPMID 35857500Read ↗

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastomaSemantic proximity Read ↗

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitorsSemantic proximity Read ↗

<i>MYCN</i> Amplification and <i>ATRX</i> Mutations are Incompatible in NeuroblastomaSemantic proximity Read ↗

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.Semantic proximity Read ↗

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma FormationSemantic proximity Read ↗

MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumorsSemantic proximity Read ↗

DNA repair and replicative stress addiction in neuroblastomaSemantic proximity Read ↗

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable OutcomeSemantic proximity Read ↗

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.Semantic proximity Read ↗

HMMR is an independent prognostic indicator in neuroblastoma and loss of HMMR suppresses cell proliferation, migration and clonogenicity.Semantic proximity Read ↗

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Semantic proximity Read ↗

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCNSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.